3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neuroblastoma
4
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
10
Temozolomide
8
X-Rays
7
Specimen Handling
7
Irinotecan
7
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Carboplatin
5
Biopsy
5
fludarabine
4
Nuclear Medicine Department, Hospital
4
olaparib
3
fludarabine phosphate
3
etoposide phosphate
3
dinutuximab
3
Zoledronic Acid
3
Oxaliplatin
3
Nivolumab
3
Ifosfamide
3
Granulocyte Colony-Stimulating Factor
3
Gemcitabine
3
Etoposide
3
Docetaxel
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
lorukafusp alfa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
IL32 protein, human
×
CNS
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts